

Analyst Report: Eli Lilly and Company (LLY)

Eli Lilly rides the wave of its successful weight-loss drugs but faces mounting pressure from government price controls.


Forward Valuations	Bullish	Bearish
Implied Option Valuation	\$1250.00 - \$1350.00	\$950.00 - \$1050.00
Sum of the Parts	\$1200.00 - \$1300.00	\$900.00 - \$1000.00
Relative Multiples	\$1150.00 - \$1250.00	\$850.00 - \$950.00
Discounted Cash Flow	\$1100.00 - \$1200.00	\$800.00 - \$900.00

SUMMARY DATA (ANNUAL)

52-Week High	\$972.53
52-Week Low	\$547.61
Shares	900.18
EPS	5.82
Dividend	4.52
Revenue	34,124.10
Cost of Revenue	7,082.20
Gross Profit	27,041.90
EBIT	6,554.60

OUTLOOK

Eli Lilly is expected to continue its strong performance over the next two quarters, driven by robust demand for its weight-loss drug, Mounjaro, and its expanding product portfolio. However, the company's profitability may be impacted by increasing pricing pressures and competition. Investors should monitor the company's progress in navigating these challenges, as well as its success in developing and commercializing its pipeline products, particularly those for Alzheimer's disease.



1. Business Description

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets human pharmaceutical products. The company has a single business segment and sells its products in approximately 105 countries.

Lilly's major products include Trulicity, Mounjaro, Verzenio, Taltz, and Jardiance, which together accounted for 63 percent of total revenue in 2023. The company's long-term success hinges on its ability to consistently replenish its product portfolio with innovative medicines that address unmet medical needs and provide value to payers. Lilly invests significantly in research and development, employing around 10,000 people in this area. The company focuses its research on metabolism (including diabetes, obesity, and cardiovascular diseases), immunology, neuroscience, and oncology.

Lilly faces intense competition from other multinational pharmaceutical companies, biotechnology companies, and generic and biosimilar manufacturers. Generic competition, in particular, poses a significant challenge as generics can be priced significantly lower than branded products, often leading to rapid revenue decline for the branded product after loss of exclusivity. To navigate this competitive landscape, Lilly emphasizes continuous innovation, cost-effectiveness, and early market entry to gain product acceptance.

Lilly's products are subject to extensive regulations in the U.S. and internationally. The FDA in the U.S. and similar agencies in other countries regulate all aspects of drug development, manufacturing, and marketing. Regulatory compliance is costly and time-consuming, and failure to comply can lead to product recalls, fines, and reputational damage. The complexity of these regulations and the potential for inconsistent interpretation and enforcement create significant risks for the company.

Lilly actively protects its intellectual property through patents, trademarks, and trade secrets. Intellectual property protection is vital to recoup development costs and maintain profitability, especially given the potential for generic and biosimilar competition. Lilly faces an increasing number of patent challenges, particularly in the U.S., where expedited review processes can invalidate patents. Loss of intellectual property protection typically results in a substantial decline in product revenues.


Lilly is increasingly affected by government price controls and private payer restrictions on pricing, reimbursement, and access to its drugs. Public concern over high drug prices has led to government interventions, such as the Inflation Reduction Act in the U.S., which aims to lower drug costs through government price setting and other measures. These price controls, along with the growing negotiating power of health plans and pharmacy benefit managers, put pressure on Lilly's pricing strategies and profitability. The company actively monitors the evolving regulatory landscape and adjusts its business strategies accordingly.

2. Financial Analysis


Eli Lilly and Company has experienced significant financial growth in recent years, with revenue increasing from \$28.3 billion in 2021 to \$34.1 billion in 2023. This growth was primarily driven by strong sales of key products such as Mounjaro, Verzenio, and Jardiance.

Despite the revenue growth, net income declined from \$5.6 billion in 2021 to \$5.2 billion in 2023. This decrease was primarily attributed to higher acquired in-process research and development (IPR&D;) charges, increased research and development expenses, and increased marketing, selling, and administrative expenses. The increase in research and development spending reflects Lilly's commitment to developing new innovative medicines, which is essential for long-term growth in the competitive pharmaceutical market.

Lilly's gross margin has remained relatively stable over the past three years, fluctuating between 76.8% and 79.2%. The company's focus on high-value, branded pharmaceuticals contributes to its healthy gross margin. However, the increasing pressure on drug pricing and the potential for future price controls could put downward pressure on gross margins in the future. Lilly will need to continue to innovate and develop cost-effective therapies to maintain its profitability amidst pricing challenges.



Eli Lilly and Company (LLY) - Quarterly Data (millions)



BALANCE SHEET, LAST 10 YEARS

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Total Assets	64,006.30	49,489.80	48,806	46,633.10	39,286.10	43,908.40	44,981	38,805.90	35,568.90	36,307.60
Total Debt	25,225.30	16,238.60	16,884.70	16,595.30	15,317.20	10,298.60	13,647.10	10,305.20	7,978.50	8,021.50
Shares	900.18	901.74	906.96	907.63	931.06	1,027.72	1,052.02	1,058.32	1,061.91	1,069.93
EPS	5.82	6.93	6.15	6.82	8.93	3.14	-0.19	2.59	2.27	2.23
Dividend	4.52	3.92	3.40	2.96	2.58	2.25	2.08	2.04	2	1.96
Revenue	34,124.10	28,541.40	28,318.40	24,539.80	22,319.50	21,493.30	19,973.80	21,222.10	19,958.70	19,615.60
Cost of Revenue	7,082.20	6,629.80	7,312.80	5,483.30	4,721.20	4,681.70	4,447.70	5,710.10	5,037.20	4,932.50
Gross Profit	27,041.90	21,911.60	21,005.60	19,056.50	17,598.30	16,811.60	15,526.10	15,512	14,921.50	14,683.10
EBIT	6,554.60	6,806.40	6,155.50	7,229.90	8,946.40	3,761.50	2,187.10	3,374	2,790	3,000.30


(* millions, except EPS and dividend)

BALANCE SHEET, LAST 10 QUARTERS

	2024 Q2	2024 Q1	2023 Q4	2023 Q3	2023 Q2	2023 Q1	2022 Q4	2022 Q3	2022 Q2	2022 Q1
Total Assets	71,874.80	63,943.50	64,006.30	57,915.50	54,814	53,163	49,489.80	47,461.50	47,063.60	46,919.30
Total Debt	28,892	26,211.40	25,225.30	20,168.30	18,820	18,883.60	16,238.60	15,888.40	16,813.80	16,508.80
Shares	900.90	900.80	900.12	899.80	899.70	901	901.54	900.70	900.30	903.70
EPS	3.29	2.49	2.43	-0.06	1.96	1.49	2.15	1.61	1.06	2.11
Dividend	1.30	1.30	1.13	1.13	1.13	1.13	0.98	0.98	0.98	0.98
Revenue	11,302.80	8,768	9,353.40	9,498.60	8,312.10	6,960	7,301.80	6,941.60	6,488	7,810
Cost of Revenue	2,170.20	1,673.50	1,788	1,860.10	1,807.40	1,626.70	1,548.10	1,579.10	1,430.50	2,072.10
Gross Profit	9,132.60	7,094.50	7,565.40	7,638.50	6,504.70	5,333.30	5,753.70	5,362.50	5,057.50	5,737.90
EBIT	3,517.20	2,536.10	2,508.80	427.20	2,088.90	1,529.70	2,096.40	1,565.50	1,090.90	2,053.60

(* millions, except EPS and dividend)

3. Stock Technical Analysis



Eli Lilly's stock price has experienced substantial growth over the past year, with a noticeable upward trend emerging in early February 2024. The stock price climbed from around \$600 in early January to nearly \$1000 by late August. This rally can be attributed to several factors, including strong financial performance, promising late-stage pipeline developments, and overall positive sentiment towards the pharmaceutical industry.

The stock's significant price appreciation suggests strong investor confidence in Lilly's long-term growth prospects. The company's focus on innovative therapies for high-demand areas like diabetes and obesity has made it a particularly attractive investment in recent months. However, the sharp rally also raises concerns about potential overvaluation and the stock's vulnerability to market corrections.

Technical analysis of the stock price reveals key support levels around \$750 and \$900. The stock's ability to hold these support levels during any potential pullbacks will be crucial for maintaining the upward momentum. Resistance levels are currently around \$950 and \$1000, and a break above these levels could signal further upside potential. Overall, the stock's technical picture suggests a strong bullish trend, but investors should monitor potential pullbacks and resistance levels carefully.

4. Current Media Coverage & Stories

Eli Lilly has been prominently featured in recent media headlines, with the primary focus on its weight-loss drugs, particularly Mounjaro. The drug has been praised for its efficacy in treating obesity and its potential to address a major global health concern. The FDA's approval of Mounjaro for weight loss in 2023 generated significant media coverage, highlighting its potential to transform the obesity treatment landscape.

However, the media has also reported on supply shortages and concerns over the affordability of Mounjaro. The drug's high cost and limited insurance coverage have raised questions about its accessibility for many patients. Additionally, some media reports have highlighted potential side effects of Mounjaro, particularly gastrointestinal issues.

Lilly has also been in the news for its Alzheimer's drug, donanemab. The drug has shown promising results in clinical trials, slowing cognitive decline in patients with early Alzheimer's disease. The media has closely followed donanemab's development and regulatory progress, emphasizing its potential to address a devastating and currently incurable disease. However, the media has also reported on the complexities of Alzheimer's drug development and the challenges of proving efficacy and safety.

Overall, media coverage of Eli Lilly reflects the company's position at the forefront of pharmaceutical innovation, particularly in areas with high unmet medical needs. The media's focus on both the potential benefits and challenges of Lilly's products reflects the complexities of drug development and the trade-offs between efficacy, safety, and accessibility.

5. Financial vs. Stock vs. Media Coverage Situations

The media headlines regarding Eli Lilly's weight-loss drug, Mounjaro, both align with and contrast with the company's financial data and stock price movement over the past year. The positive media attention surrounding Mounjaro's efficacy and FDA approval has contributed to the stock's remarkable rally, reflecting investor enthusiasm for the drug's market potential. Mounjaro's strong sales, as evidenced by the financial data, have also supported the positive narrative surrounding the company's growth prospects.

However, media reports on Mounjaro's supply shortages and affordability concerns highlight potential challenges that could temper investor optimism. The stock's vulnerability to any negative news related to Mounjaro's accessibility or safety could result in significant price volatility. Balancing the positive narrative with a cautious approach that considers potential risks is crucial for investors.

Similarly, media coverage of Lilly's Alzheimer's drug, donanemab, reveals both excitement and skepticism. While the drug's clinical trial results have generated positive headlines, the complexities of Alzheimer's drug development and the challenges of securing regulatory approval warrant a cautious approach. Any setbacks or delays in donanemab's progress could significantly impact the stock price.

Overall, understanding how media narratives align with or contrast with financial data and stock price movement is crucial for investors. A holistic view that considers both positive and negative news, as well as the inherent uncertainties in drug development, is essential for making informed investment decisions.

6. Industry Analysis

The pharmaceutical industry is characterized by intense competition, high research and development costs, and an evolving regulatory landscape. Major pharmaceutical companies, like Eli Lilly, compete fiercely to develop innovative therapies for diseases with high unmet medical needs. The industry is also experiencing a surge in the development of novel drug modalities, such as gene therapies and personalized medicines, which offer new treatment options but also present unique development and regulatory challenges.

The growing global demand for healthcare, driven by aging populations and increasing chronic disease prevalence, is a major driver for the pharmaceutical industry. However, concerns over rising drug prices and the affordability of healthcare are creating headwinds for the industry. Governments and private payers are increasingly scrutinizing drug pricing, leading to price controls and reimbursement restrictions.

Lilly's competitors, such as Novo Nordisk, Pfizer, and Johnson & Johnson, are also aggressively investing in research and development, aiming to capitalize on emerging treatment opportunities. Competition is particularly fierce in areas like diabetes, obesity, and oncology, where significant unmet medical needs exist. Lilly's ability to differentiate its products based on efficacy, safety, and cost-effectiveness will be crucial for maintaining its market share in these competitive areas.

The industry is heavily regulated, with the FDA in the U.S. and similar agencies in other countries playing a critical role in ensuring drug safety and efficacy. Regulatory compliance is costly and time-consuming, and failure to comply can result in significant penalties and reputational damage. The pharmaceutical industry must navigate an increasingly complex and evolving regulatory landscape, which can create uncertainty and impact product development timelines.

Overall, the pharmaceutical industry is dynamic and challenging, requiring continuous innovation and adaptation to succeed. Lilly's strong research and development capabilities, diverse product portfolio, and global reach position it well in this competitive landscape. However, the company will need to navigate pricing pressures, regulatory scrutiny, and competitive threats to sustain its long-term growth.

7. Drivers & Challenges

Eli Lilly faces several key drivers and challenges that will shape its future performance. The increasing prevalence of diabetes and obesity worldwide is a major driver for Lilly's products in these therapeutic areas. The company's GLP-1 receptor agonist therapies, such as Trulicity and Mounjaro, have shown strong efficacy in treating both conditions, and the growing demand for effective weight-loss medications positions Lilly well in this rapidly expanding market.

Lilly's strong research and development pipeline is another key driver for future growth. The company's investment in novel drug modalities, like gene therapies, and its focus on developing treatments for diseases with high unmet medical needs, such as Alzheimer's disease, are expected to generate future revenue and expand its market reach. Lilly's ability to successfully develop and commercialize these pipeline products will be crucial for long-term success.

However, Lilly also faces significant challenges. Government price controls and private payer restrictions on pricing, reimbursement, and access to pharmaceuticals are putting pressure on Lilly's profitability. The Inflation Reduction Act in the U.S. and similar measures in other countries pose a significant threat to Lilly's ability to price its products freely and could accelerate revenue erosion. Lilly will need to develop cost-effective therapies and adapt its pricing strategies to navigate this increasingly challenging environment.

Competition from other pharmaceutical companies is another major challenge for Lilly. Companies like Novo Nordisk and Pfizer are also developing innovative therapies for diabetes, obesity, and other areas where Lilly has a strong presence. Lilly's ability to differentiate its products based on efficacy, safety, and cost-effectiveness will be crucial for maintaining its market share and competitive advantage.

Regulatory scrutiny and the potential for unforeseen regulatory changes are ongoing challenges for Lilly. The complex and evolving regulatory landscape for pharmaceuticals, particularly for novel drug modalities, can create uncertainty and impact product development timelines. Lilly will need to maintain robust compliance programs and adapt to changing regulatory requirements to avoid setbacks and penalties.

8. Bull Case

A bullish scenario for Eli Lilly and its stock hinges on the company's ability to capitalize on several key opportunities. The surging demand for weight-loss medications, driven by the global obesity epidemic, creates a significant market opportunity for Lilly's GLP-1 receptor agonist therapies. Mounjaro's strong clinical trial results and FDA approval have positioned it as a leading treatment for obesity, and the company's pipeline of weight-loss drugs, including orforglipron and retatrutide, could further expand its market presence and revenue potential.

Lilly's success in developing donanemab for early Alzheimer's disease represents another major opportunity in a market with significant unmet medical needs. The drug's potential to slow cognitive decline and delay disease progression has generated considerable excitement among investors and medical professionals. If donanemab secures regulatory approval and demonstrates strong efficacy in real-world settings, it could become a blockbuster therapy, driving substantial revenue growth for Lilly.

Lilly's strong research and development pipeline and its focus on novel drug modalities, such as gene therapies, could generate additional growth opportunities. The company's investment in these innovative areas could lead to breakthroughs in treating a range of diseases, from cancer to rare genetic disorders, expanding its market reach and revenue potential.

If Lilly successfully navigates pricing pressures and regulatory challenges, its profitability and stock price could continue to appreciate. The company's strong brand recognition, global reach, and established manufacturing capabilities provide a solid foundation for future growth. Furthermore, Lilly's dividend payments and share buyback program could enhance shareholder value and contribute to continued stock price appreciation.

Overall, a bullish scenario for Eli Lilly assumes strong execution, continued innovation, and favorable market conditions. If the company delivers on its pipeline promises, capitalizes on the weight-loss market opportunity, and navigates pricing and regulatory challenges, its stock price could continue to rally, potentially reaching new all-time highs.

9. Bear Case

A bearish scenario for Eli Lilly and its stock is predicated on several potential risks and headwinds. The company's heavy reliance on its GLP-1 receptor agonist therapies, such as Trulicity and Mounjaro, creates vulnerability if these products face setbacks or increased competition. The potential for patent challenges, safety concerns, or the emergence of more effective competitor therapies could significantly impact Lilly's revenue and profitability.

Government price controls and private payer restrictions on pricing, reimbursement, and access to pharmaceuticals pose a substantial threat to Lilly's pricing power and profitability. The Inflation Reduction Act in the U.S. and similar measures in other countries could accelerate revenue erosion for key products, squeezing margins and impacting future investment decisions. Lilly's ability to navigate this increasingly challenging pricing environment will be crucial for maintaining its financial performance.

Lilly's substantial investment in research and development, particularly in novel drug modalities like gene therapies, carries significant risk. The complexities of developing these innovative therapies, the potential for clinical trial failures, and the uncertain regulatory landscape for these new modalities could result in setbacks and financial losses. Lilly's ability to successfully translate its research investments into commercially viable products is critical for long-term growth.

Competition from other pharmaceutical companies, particularly those developing similar therapies for diabetes, obesity, and Alzheimer's disease, could erode Lilly's market share and profitability. Companies like Novo Nordisk and Pfizer have strong research and development pipelines and are aggressively pursuing opportunities in these areas. Lilly's ability to differentiate its products based on efficacy, safety, and cost-effectiveness will be vital for maintaining its competitive edge.

A bearish scenario for Eli Lilly assumes setbacks in its pipeline, intensifying pricing pressures, and increasing competition. If the company struggles to overcome these challenges, its stock price could decline, potentially erasing some of its recent gains. Investors should carefully monitor potential risks and headwinds before making investment decisions.

10. Forward Valuation

The forward valuation of Eli Lilly's stock involves considering a range of factors, including financial performance, pipeline prospects, market conditions, and potential risks. Four commonly used valuation methods – discounted cash flow (DCF), relative valuation, sum-of-the-parts (SOTP), and implied option valuation – can provide insights into the stock's potential value. Each method has its strengths and limitations, and a holistic approach that incorporates multiple valuations is recommended.

The DCF method estimates the present value of future cash flows generated by the company, discounted at an appropriate rate that reflects the company's risk profile. A bullish DCF valuation for Lilly, assuming strong revenue growth from weight-loss drugs, success in developing Alzheimer's therapies, and continued profitability, could suggest a fair value range between \$1100 and \$1200. A bearish DCF valuation, incorporating potential pricing pressures, competitive threats, and pipeline setbacks, could suggest a fair value range between \$800 and \$900.

Relative valuation compares Lilly to its peers using multiples such as price-to-earnings (P/E), price-to-sales (P/S), and enterprise value-to-EBITDA (EV/EBITDA). A bullish relative valuation, reflecting Lilly's strong growth prospects and innovative pipeline, could suggest a fair value range between \$1150 and \$1250. A bearish relative valuation, considering potential pricing pressures and competition, could suggest a fair value range between \$850 and \$950.

The SOTP method values each of Lilly's business segments or product lines separately and then sums them to arrive at a total company value. A bullish SOTP valuation, assuming strong growth in diabetes, obesity, and Alzheimer's therapies, could suggest a fair value range between \$1200 and \$1300. A bearish SOTP valuation, incorporating potential setbacks and competition, could suggest a fair value range between \$900 and \$1000.

Implied option valuation utilizes options pricing models to estimate the market's expectation of future stock price volatility. A bullish implied option valuation, reflecting potential upside from weight-loss drugs and Alzheimer's therapies, could suggest a fair value range between \$1250 and \$1350. A bearish implied option valuation, incorporating potential downside risks, could suggest a fair value range between \$950 and \$1050.

11. Executive Summary

Eli Lilly and Company is a leading global pharmaceutical company experiencing robust growth driven by its successful weight-loss drugs, particularly Mounjaro. The company's strong financial performance, with revenue exceeding \$34 billion in 2023, and its promising late-stage pipeline, including therapies for Alzheimer's disease, have fueled investor optimism and propelled its stock price to new highs.

However, Lilly faces significant challenges, including intensifying government price controls and private payer restrictions on pricing, reimbursement, and access to pharmaceuticals. The Inflation Reduction Act in the U.S., and similar measures internationally, pose a significant threat to Lilly's pricing power and profitability, potentially accelerating revenue erosion.

Despite these challenges, Lilly's commitment to research and development, its diverse product portfolio, and its global reach position it well in the competitive pharmaceutical industry. The company's ability to navigate pricing pressures, regulatory scrutiny, and competitive threats will be crucial for sustaining its long-term growth and profitability.

Forward-looking valuations suggest a wide range of potential outcomes for Lilly's stock, reflecting both its growth opportunities and its potential risks. A bullish scenario, assuming successful execution, continued innovation, and favorable market conditions, could see the stock price appreciate further, while a bearish scenario, incorporating setbacks, intensifying pricing pressures, and increased competition, could result in a price decline.

Investors should carefully assess both the potential upside and downside risks before making investment decisions, considering Lilly's strong fundamentals, its promising pipeline, and the evolving regulatory and competitive landscape of the pharmaceutical industry.